IDEAYA Biosciences enters exclusive license with Hengrui Pharma for SHR-4849, a novel Phase 1 DLL3 Topo-I-payload ADC targeting SCLC and NET solid tumors

CAR-T Digest - August 2020

Weekly Digest - January 2025

29 Dec 2024: IDEAYA Biosciences enters exclusive license with Hengrui Pharma for SHR-4849, a novel Phase 1 DLL3 Topo-I-payload ADC targeting SCLC and NET solid tumors

IDEAYA Biosciences has entered into an exclusive license agreement with Jiangsu Hengrui Pharmaceuticals for SHR-4849, a DLL3-targeting Topo-I-payload ADC program. IDEAYA will develop and commercialize SHR-4849 worldwide, excluding Greater China
SHR-4849 is targeting DLL3-expressing solid tumors, with potential for monotherapy use in small-cell lung cancer (SCLC) and neuroendocrine tumors (NETs). It is positioned as a first-in-class therapy in the DLL3 topo-I-payload ADC field
SHR-4849 is currently in a Phase 1 clinical trial in China for advanced solid tumors. Early clinical data shows promising antitumor activity, with a 73% overall response rate in SCLC patients at therapeutic dose levels, and manageable safety profiles
The deal includes $1.045 billion in potential payments to Hengrui, including a $75 million upfront fee, up to $200 million in development and regulatory milestones, and royalties on sales outside Greater China